References
- Tricot G. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJJ, Shattil Si. (eds) Hematology: Basic Principles and Practice, 3rd ed. Philadelphia, PA: Churchill Livingstone, 2000.
- Alexander DD, Mink Pi, Adami HO et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007; 120: 40–61.
- Bataille R, Harousseau J. Multiple myeloma. New Engl. J Medicine1997; 336: 1657–1664.
- Tricot G. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJJ, Shattil Si. (eds) Hematology: Basic Principles and Practice, 3rd ed. Philadelphia, PA: Churchill Livingstone, 2000.
- Barlogie B, Shaughnessy J, Tricot G. Treatment of multiple myeloma. Blood 2004; 103: 20–26.
- Osserman EF, Lawlor D. Serum and urinary lysozyme (murami-dase) in monocytic and monomyelocytic leukemia. J Expl Med 1966; 124: 921–926.
- Aubert E, Schmidt CG. Ferritin — a tumor marker in myeloid leukemia. In: Nieburgs HN. (ed) Tumor Markers in Cancer Control. London: BMJ Publishing Group, 1985.
- Tietz N. (ed) Clinical Guide to Laboratory Tests. Philadelphia, PA:WB Saunders Co., 1995.
- San Miguel JF, Gutierrez NC, Mateo G, Orfao A. Conventional diagnosis in multiple myeloma. Eur. J. Cancer 2006; 42: 1510–1519.
- Cisar J, Kabat EA, Liao J, Potter M. Immunochemical studies on mouse myeloma protein reactive with dextran or fructosans and on human antileva. J Expl Med 1974; 139: 159–179.
- Moscona AA. Embryonic and neoplastic cell surface. Availability of receptor for Con A wheat germ agglutinin. Science 1971; 171: 905–907.
- Fritz E, Ludwig H, Kundi M. Prognostic relevance of cellular morphology in multiple myeloma. Blood 1984; 63: 1072–1079.
- Micheel F, Wulf U. Reactions of d-glucosamine. Chem Ber 1956; 89: 1521–1530.
- Bauer RJ, Gray GR. Lectin purification on affinity colums contain-ing reductively aminated disaccharides. J Biol Chem 1977; 252: 57–60.
- Leo R, Boemeker M, Peest D. Multiparameter analysis of normal and malignant human plasma cells CD38± ±,CD56±, CD54±,c1g± is the common phenotype of myeloma cells. Ann Haemotol 1992; 64: 132–139.
- Mateo G, Castellanos M, Rasillo A. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005; 11: 3661–3667.
- Van Beek WP, Smets LA, Emmelot P. Changed surface glycoprotein as a marker of malignancy in human leukemic cells. Nature 1975; 253: 457–460.
- Cohen AM, Allalouf D, Bessler H, Dialdetti M, Malachi T, Levinsky H. Sialyltransferase activity and sialic acid levels in multiple myeloma and monoclonal gammapathy. Eur J Hematol 1989; 42: 289–293.
- Hanisch FG, Uhlenbruck G, Dienst C, Stottropa M, Hippauf E. CA 125 and CA 19-9 two cancer associated sialylsaccharide antigens on a mucus glycoprotein from human milk. Eur J Biochem 1985; 149: 323–330.
- Dotan N, Altstock RT, Schwarz M, Dukler A. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus 2006; 15: 442–450.